The recent introduction of advanced magnetic resonance (MR) imaging techniques to characterize focal and global degeneration in multiple sclerosis (MS), like the Composite Hindered and Restricted Model of Diffusion, or CHARMED, diffusional kurtosis imaging (DKI) and Neurite Orientation Dispersion and Density Imaging (NODDI) made available new tools to image axonal pathology non-invasively in vivo. These methods already showed greater sensitivity and specificity compared to conventional diffusion tensor-based metrics (e.g., fractional anisotropy), overcoming some of its limitations.
Introduction
Multiple sclerosis (MS) is a human neurological disorder with an onset most often in young adulthood that affects almost 2.5 million individuals worldwide, involving focal demyelination and axonal loss (Weinshenker 1996 , Noseworthy et al., 2000 , Ellwardt and Zipp, 2014 . With its ability to image soft tissues in vivo noninvasively, diffusion tensor imaging (DTI; Basser et al., 1994) has shown high sensitivity in detecting brain damage in MS. Using DTI, abnormalities in diffusivity patterns have been detected in focal MS lesions, normal-appearing white matter (NAWM) and grey matter (GM) (Werring et al., 1999 , Vrenken et al., 2006 . However, DTIderived scalar indices such as fractional anisotropy (FA) (Basser and Pierpaoli, 1996) lack specificity to different sub-compartments of white matter (WM) microstructure: in the context of MS, both demyelination and axonal loss have similar impact on DTI indices and can therefore not be differentiated using this technique (Wheeler-Kingshott and Cercignani, 2011) . In addition, it was recently shown that DTI accuracy is strongly affected by the experimental parameters chosen, making it difficult to interpret and merge data coming from different centers (BarrioArranz et al., 2015) .
In the last few years, several advanced diffusion-weighted imaging methods have been introduced to overcome these limitations. Diffusional Kurtosis Imaging (DKI) quantifies the deviation of the MRI signal decay from the DTI exponential model using a dimensionless metric called the excess kurtosis (Jensen et al., 2005) . Recent evidence suggests that DKI indices like the mean kurtosis are affected in MS compared to controls (Guglielmetti et al., 2016) . Moreover, significant correlations between DKI parameters and the Expanded Disability Status Scale were also reported (de Kouchkovsky et al., 2016) . The Composite Hindered and Restricted Model of Diffusion (CHARMED) (Assaf et al., 2004) separates the contributions of different intra-and extracellular water compartments to the signal decay measured in diffusion-weighted imaging, and can therefore be used to extract new biomarkers of tissue microstructure which are able to disentangle the effects of axonal loss from those due to demyelination (Assaf et al., 2004) .
CHARMED generates maps of the restricted water fraction (FR), a proxy for the axonal density, which was recently shown to provide increased specificity and sensitivity to microstructural changes happening in early MS, both in lesions and in NAWM (De Santis et al., 2017) . Along the same lines, Neurite Orientation Dispersion and Density Imaging (NODDI; Zhang et al., 2012) provides, in addition to the restricted water fraction, an index quantifying the fiber dispersion. A few recent studies used the NODDI model to investigate GM , spinal cord and WM , Schneider et al. 2017 , reporting an increase in both sensitivity and specificity in differentiating patients from controls.
The acquisition time for these advanced diffusion-weighted imaging methods is typically longer than for DTI, as they require the diffusion images to be acquired along many different gradient orientations and for at least two different b-values (Chuhutin et al., 2017; Zhang et al., 2012 : De Santis et al., 2014 , i.e., they need a multi-shell diffusion MRI acquisition. The majority of the mentioned studies were performed using advanced gradient equipment (i.e., maximum gradient intensity of 300 mT/m, De Santis et al., 2017) ; the same protocols implemented on scanners mounting conventional gradient equipment (40-80 mT/m) would result in acquisition times too long for the clinical setting to be feasible, and a drop in the signal-to-noise ratio. The remaining challenge for translation to clinics at 3T, and for inclusion into advanced pipelines at 7T, is to be able to measure these microstructural changes under more conventional gradient settings.
Employing an efficient pipeline is extremely important because it dramatically affects the accuracy and precision of the measured biomarkers. In the context of MS, improved accuracy and precision can potentially uncover early tissue changes invisible to conventional approaches. In addition, an optimal scheme can reduce the acquisition time, which is critical for ensuring feasibility of advanced diffusion MRI methods in clinical studies, possibly also in a multi-center design and, ultimately, to pave the way for their inclusion into clinical routine. However, this theme is often disregarded due to the high complexity of the model parameters optimization; a few studies have proposed optimal experimental designs for multi-shell techniques (Alexander et al., 2010 , Prčkovska et al., 2012 Zhang et al., 2012 , De Santis et al., 2014 , Chuhutin et al., 2017 , but these were not yet applied to MS patient studies. In addition, the differential ability of various diffusion-based imaging biomarkers to highlight microstructural abnormalities present in MS tissue compared to healthy controls has not yet been investigated.
Here, we employed two optimized multi-shell diffusion protocols at two different fields (7T vs. 3T) to measure several MRI biomarkers in a cohort of MS patients and a matched cohort of healthy controls, with the aim of identifying the protocol that best distinguishes tissue differences in lesions, NAWM and normal appearing grey matter (NAGM) compared to healthy controls. For the CHARMED model, the only tested model for which very high (>3000 s/mm 2 ) b-values can be beneficial, two different acquisition protocols proposed in recent literature, at low (Zhang et al., 2012 ) and very high b-value (De Santis et al., 2014) , were also tested.
This work is expected to impact future choices for investigating MS WM microstructure in larger cohorts, follow-ups or focusing on specific stages of the disease, and for selecting the appropriate experimental framework to obtain optimal data quality for the allocated time.
Experimental procedures

Data acquisition
Seven MS patients and six age-matched healthy controls underwent a comprehensive MRI protocol in two different sessions, scheduled no more than 48 hours apart. All MS patients were in the early phase of the disease (duration ≤ 3 years) and had been diagnosed with relapsingremitting MS. At the time of scanning, three were receiving medical treatment with interferon beta-1a, two with natalizumab, one with mitoxantron and one with glatiramer acetate.
Participants' demographic and clinical characteristics are reported in was used for all diffusion protocols with multiband factor 2 and generalized autocalibrating partial parallel acquisition (GRAPPA) factor 2 (Moeller et al., 2010; Xu et al., 2013) . Throughout this work, the first multi-shell protocol will be addressed as "low-b protocol" while the second multi-shell protocol will be addressed as "high-b protocol". Total acquisition time was around 30 minutes.
The second session was acquired on a 7T Magnetom Siemens scanner. To minimise the effects of B1 inhomogeneity, dielectric pads (Teeuwisse et al., 2012) were placed between the subject's head and the coil, positioned in correspondence with temporal and occipital lobes, i.e., the brain areas most affected by such inhomogeneity in a volume transmit coil. The session comprised: an anatomical MP2RAGE scan, resolution 0.7 mm isotropic, TE/TR 2.47/5000 ms, scan duration 10 minutes; a multi-shell diffusion with b=700/2000 s/mm 2 and 27/45 gradient orientations, plus two unweighted scans with forward phase encoding and six unweighted scans with reversed phase orientation, at 1.5 mm isotropic resolution, TE/TR 60/7500 ms, scan duration 10 minutes; a WM Double Inversion Recovery (DIR; Pracht et al., 2017) scan with resolution 1 mm isotropic, TE/TR 163/3000, scan duration 8 minutes; a GM DIR scan with resolution 1 mm isotropic, TE/TR 163/3000, scan duration 8 minutes. GRAPPA was used with factor 2. Total acquisition time, comprising also adjustment time, was around one hour. Due to the need to keep the examination time within one hour, and because of the higher penalty of long-TE high b-value diffusion scan (the relaxation time T 2 is shorter at higher fields) it was not possible to acquire a high-b diffusion protocol at 7T.
Data processing and normalization
Diffusion data were pre-processed using FSL TOPUP and EDDY (Andersson et al., 2003; Andersson et al., 2016) to correct for susceptibility-induced distortions, eddy currents and subject motion. Signal-to-Noise Ratio (SNR) values in the b0 images were calculated for each diffusion protocol in the whole brain using the difference method (Murphy et al., 1993) , returning: Conventional DTI data analysis was performed with the ExploreDTI software (Leemans et al., 2009 ) using only the b=700 s/mm 2 shell; from the tensor, maps of FA were obtained. Only low-b protocols were used to estimate FA, since the DTI model is not appropriate for b-values>1500 s/mm 2 (Jones et al., 1999) .
Subsequently, all diffusion data at both fields was employed for multi-shell diffusion analysis.
The kurtosis model was fitted using FSL's FDT (Jenkinson et al., 2012) to obtain the mean kurtosis (MK), while NODDI maps of restricted volume fraction (FR NODDI ) and orientation dispersion (ODI) were fitted using the software MDT (https://github.com/cbclab/MDT, version 0.10.6) using the Cascade Initialized optimization strategy (Harms et al., 2017 ). The CHARMED model was fitted using in-house software written in Matlab R2015b (The Mathworks). The CHARMED fitting procedure was based on nonlinear least square estimation using a Levenberg- In the MS group, lesions were segmented manually and carefully checked by a trained radiologist using the two DIR images at 7T, where the lesions are hyper-intense in the GM-DIR and hypointense in the WM-DIR, as shown in Figure 2 . Lesions were only scored above 3 voxels in size based on at least 1 mm 2 in-plane resolution, according to recent consensus recommendations (Geurts et al., 2011) , but lesions smaller than 12 voxels in volume were not taken into account in the statistics, in order to forego possible co-registration inaccuracies. The lesion masks were then transferred into the diffusion space according to the following procedure: the WM DIR maps were registered to the MPRAGE maps (for 3T) or to the MP2RAGE maps (for 7T); then, the diffusion unweighted scans (i.e., b0s) were registered to the MPRAGE and MP2RAGE
anatomical scans, and the inverse transformation was calculated. All the transformations employed at this stage were rigid body (6 degrees of freedom); the cost function chosen was the Correlation Ratio and all the brains were extracted using FSL BET software (Jenkinson and Smith, 2001 ) prior to registration. The two transformations were combined and applied to the lesion masks. All the aforementioned registration steps were performed using FSL FLIRT software (Jenkinson and Smith, 2001) ; the registration pipeline is illustrated in Fig. 2e.
All FA maps were then nonlinearly warped to the FMRIB58 FA template using ANTs (Klein et al., 2009) . Importantly, the co-registration procedure excludes lesion masks from the computation of the figure of merit employed in the optimization procedure that calculates warp fields, so that the normalization is accurate also for MS subjects. The same transformation was applied to all the other biomarkers (MK, FR NODDI , ODI, FR CHARMED ) and to the lesion masks.
To compare NAWM in MS patients and controls, the WM skeleton was calculated using parts of the TBSS pipeline (Smith et al., 2006) combined with an automatic ROI (region of interest) selection using WM labelling in standard space (JHU ICBM DTI 81 Atlas, also available in FSL), a procedure described previously (De Santis et al., 2012) . To compare NAGM between MS patients and controls, a similar approach was employed using the GM parcellation in Brodmann areas available in ExploreDTI (Leemans et al., 2009) .
Mean values and standard deviations were calculated for each parameter (MK, FR NODDI , ODI, FR CHARMED ) and each protocol (3T/low-b, 3T/high-b and 7T/low-b) in the following regions: 1) in each ROI belonging to the WM skeleton for controls and MS (in MS, lesions were excluded); 2)
in each ROI belonging to the GM parcellation for controls and MS (in MS, lesions were excluded); and 3) in each lesion from the masks for MS patients and in the corresponding registered ROI from healthy controls.
Statistical analysis
Analysis of variance (ANOVA) was used to assess whether the applied protocol had a significant effect on the measured parameters. Within-subject effect was the protocol (3T and 7T for FA, MK, FR NODDI , ODI and 3T/low-b, 3T/high-b and 7T/low-b for FR CHARMED ) and between-subject effect was the tissue kind (healthy, NAWM, NAGM, lesion). SNR was included as covariate of no interest in the analysis.
Given that different anatomical locations present different baseline values for each parameter, in order to render differences between MS lesions and corresponding ROIs in healthy controls comparable, we calculated the difference between the two values and divided it by the reference value in healthy controls, according to the following formula:
P NORM =(P MS lesion mask -P healthy lesion mask ) / P healthy lesion mask
Were P is the parameter (FA, MK, FR NODDI , ODI, FR CHARMED in this study). The null hypothesis of no difference between lesions and healthy tissue was then tested across patients through a nonparametric signed-rank test. Likewise, the group effect was tested in 50 ROIs from the JHU ICBM DTI 81 atlas (Mori et al., 2008) , projected onto the WM skeleton, using a nonparametric signed-rank test, and on 41 Brodmann areas in GM. The effect size was calculated as the difference between the biomarker values in the MS group and in the healthy control group, divided by the pooled standard deviation (Cohen's d). Post-hoc comparisons between groups were performed using the Mann-Whitney test, under the assumption that the presence of the disease causes a decrease in the measured imaging parameters (left tail only). Multiple comparisons were corrected for the false discovery rate (Benjamini and Yekutieli, 2005 
Results
Mean biomarkers value and ANOVA
Mean values and standard deviations for the investigated biomarkers, in the whole WM skeleton, in the GM areas and in the lesion masks, are reported in Table 2 . In Table 3 Figure 3 shows the values of FA, MK, FR NODDI , ODI and FR CHARMED in lesions and in the corresponding healthy tissue in the control cohort across the different tested protocols; in the boxplot, the reported statistic indicates significant differences between the two cohorts in the nonparametric signed-rank test. All indices show significant differences for both tested protocols.
Differences between MS lesions and healthy control tissue
Lesions, as expected, are characterised by higher standard deviation compared to control values.
Differences between NAWM and healthy control tissue
All indices show significant differences between NAWM and the corresponding healthy tissue in the control cohort at 3T except ODI, while FA, ODI and FR from CHARMED and FR from NODDI show significant differences at 7T. The boxplots and the corresponding nonparametric signed-rank test statistics are reported in Figure 4 .
Differences between NAGM and healthy control tissue
In NAGM, MK, ODI, FR from NODDI and FR from CHARMED at high-b show significant differences between healthy controls and MS at 3T, while at 7T only FA, FR from NODDI and ODI show significant differences between the two cohorts. The boxplots and the corresponding nonparametric signed-rank test statistics are reported in Figure 5 .
Effect size
The effect size, for all microstructural parameters and across the tested protocols, for the combinations with statistically significant decrease according to the post-hoc test, is reported in 
Discussion
In this work, we employed three different multi-shell diffusion MRI protocols at two field strengths to measure five microstructural MRI parameters from a range of models (FA, MK, FR NODDI , ODI and FR CHARMED ) in a cohort of MS patients and a matched cohort of healthy controls, with the aim of identifying the protocol and the biomarker that best mirrors tissue differences in the inflammatory lesions, in NAWM and NAGM compared to healthy controls.
The first result, replicating recent findings obtained in a high-end set-up (De Santis et al., 2017) , is that under clinical settings more sophisticated microstructural measures (FR CHARMED , FR NODDI, and MK) are a better descriptor than FA for the underlying tissue alterations in both lesions and NAWM. The fact that FR CHARMED , FR NODDI, and MK differences are significant also in the relatively small cohort analysed in this study adds to the translational potential of these multi-shell methods for the clinical routine. Interestingly, while there are no major differences between the performances of the low b-value protocols across fields, our results suggest that the short-time high b-value protocol is not optimal for microstructural analysis in MS. Furthermore, we show that a 10-minute multi-shell diffusion protocol at 7T has similar performance in MS when compared to its counterpart at 3T, which is commonly considered the best option. There are no differences in FR CHARMED between NAGM and corresponding GM areas; this is expected as the model is specifically formulated to account for the geometry of WM.
FR NODDI gives similar results as FR CHARMED , although the differences for FR NODDI in NAWM are not significant at 7T. ODI gives complementary information about the neurite dispersion in both GM and WM and it has been proposed as a novel tool to capture microstructural changes in both NAWM and lesions in MS (Schneider et al., 2017) . Increased ODI in NAWM and decreased ODI in lesions were reported in a small cohort (Schneider et al., 2017) , but another larger study found no differences in normal-appearing tissue and an increase in lesions . Here, we found a trend of reduced ODI in both MS WM and GM compared to controls, which however is not statistically significant. Taken together, these results suggest that more studies with larger cohorts are needed to characterize the ODI as a putative marker for MS.
MK is reduced in MS compared to controls in lesions, NAWM and NAGM at 3T, and only in lesions at 7T. The reduction of MK in MS tissue compared to controls is in agreement with recent work (Guglielmetti et al., 2016; Qian et al., 2016) . Recent findings (Chuhutin et al., 2017) highlighted that precision and accuracy on MK are highly dependent on the proper choice of bvalues; the ones employed in this study are optimal for WM, but suboptimal for GM. Repeating the experiment using a protocol with lower b-value might provide further insights into the differences in kurtosis in NAGM compared to controls.
The effect size in lesions, as expected, is always larger compared to NAWM and NAGM.
Nonetheless, most of the multi-shell microstructural parameters show differences in NAWM, and some also in NAGM, while FA does not capture significant differences. While the lack of results using conventional DTI might be certainly due to the relatively small cohort employed in this study, or to the choice of b-value, it is important to note that multi-shell diffusion imaging has enough sensitivity to highlight differences between healthy and lesioned tissue also with low sample sizes, with huge potential for the clinical routine.
The main differences between the different tested protocols are: 1) the SNR of the images, affected by both the field magnitude and the echo time; 2) the diffusion contrast, which depends on the applied b-value; and 3) the echo time, which can change the proportion between tissue compartments with different T 2 relaxation times (De Santis et al., 2016) .
There are differences between the SNRs across protocols, but these do not fully explain the , 2011 , De Santis et al., 2014 , the results obtained here suggest that in the context of early-stage MS they may not be the best choice. We speculate that this might depend on inflammation-related differences in the T 2 relaxation time between normal and damaged tissue (van Waesberghe et al., 1999) , given that a long echo time (required for high b-values on clinical gradients) changes the proportion between tissue compartments with different T 2 relaxation times (De Santis et al., 2016) . The situation can be different for more advanced configurations, like gradients with intensity even higher than 70-80 mT/m, which achieve a TE reduction for high bvalues, for long-time protocols, or for further advances which significantly increase the speed of imaging. Our results also suggest that the high b-value protocol can be useful when looking at GM.
Importantly, our findings support the feasibility of CHARMED, NODDI and DKI at 7T. With the numerous further advantages in other (e.g., functional) MRI imaging contrasts, ultra-high field is rapidly emerging as the high-end instrument for neuroimaging. 7T is sometimes considered to be of limited benefit for diffusion, but recent studies demonstrated that SNR differences across similar diffusion protocols at 3T and 7T are minimal (Wen et al., 2015) , and that 7T can even be advantageous when high gradient intensity (i.e., >70 mT/m) is available (Ugurbil et al., 2013) .
The results presented here might also contribute to explaining the discrepancy in the findings of different diffusion MRI studies in MS, which can be at least partially attributed to differences in the protocols used, and lay the ground for the standardization of diffusion protocols in MS.
Conclusions
Multi-shell diffusion acquisitions increased the ability to detect axonal pathology occurring in MS brain tissue compared to conventional DTI in a small pilot study, also under clinical settings.
In addition, our findings suggest that multi-shell diffusion MRI at both high (3T) and ultra-high 
